@article{Atak_Ulu_Kazan_Polat_2020, title={Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients}, volume={3}, url={https://experimentalbiomedicalresearch.com/ojs/index.php/ebr/article/view/110}, DOI={10.30714/j-ebr.2020361048}, abstractNote={<p><strong>Aim:</strong> To evaluate the effectiveness of contrast-induced acute kidney injury (CI-AKI) prophylaxis retrospectively, using calcium channel blockers (CCB) before and after contrast exposure and comparing them with patients using angiotensin converting enzyme inhibitors (ACEI), which has not been explored by many studies.</p> <p><strong>Methods:</strong> The study was performed in Afyon Kocatepe University, Faculty of Medicine Research Hospital, Cardiology Department between January 2014 and June 2016. Eighty patients using dihydropyridine (amlodipine 10 mg), non-dihydropyridine (diltiazem 60 mg) CCB or ACEI in the form of monotherapy before coronary angiography were included.</p> <p><strong>Results:</strong> In the CCB and ACEI group, CI-AKI development rates were 15.7% (n=8) and 24.1% (n=7), respectively <em>(p = 0.383; Fisher’s exact test)</em>. When the CCB group was evaluated as dihydropyridine and non-dihydropyridine subsets, CI-AKI development rates were found to be similar as well <em>(p = 0.445; Fisher’s exact test)</em> in each subset.</p> <p><strong>Conclusion:</strong> In our study, we evaluated one of today’s important dilemma; the methods related to the prophylaxis of CI-AKI. Our study shows that there is no difference in the development of CI-AKI between patients using the calcium channel blocker group drugs and ACEI as monotherapy. However, in our study, the mean age of patients using CCB was significantly higher than the group using ACEI.</p>}, number={3}, journal={EXPERIMENTAL BIOMEDICAL RESEARCH}, author={Atak, Burcin Meryem and Ulu, Memnune Sena and Kazan, Sinan and Polat, Mehmet}, year={2020}, month={Jun.}, pages={133–140} }